MEKK2 mediates aberrant ERK activation in neurofibromatosis type I
MEKK2 mediates aberrant ERK activation in neurofibromatosis type I
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Neurofibromatosis type I (NF1) is characterized by prominent skeletal manifestations caused by
NF1
loss. While inhibitors of the ERK activating kinases MEK1/2 are promising as a means to treat NF1, the broad blockade of the ERK pathway produced by this strategy is potentially associated with therapy limiting toxicities. Here, we have sought t...
Alternative Titles
Full title
MEKK2 mediates aberrant ERK activation in neurofibromatosis type I
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_1bdc5e8883dd407b82aab19c4cfb975b
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1bdc5e8883dd407b82aab19c4cfb975b
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-020-19555-6
